Inhibikase Therapeutics is slamming the brakes on its Parkinson’s disease program after the candidate failed to improve symptoms in a mid-stage test in treatment-naïve patients.
The biotech’s risvodetinib didn’t meet the Phase 2 trial’s key ...
↧